baber/WOPTO huggingface dataset:
Patent NZ-564177-A (NZ)
Title: Contrast fluid delivery system with a disposable set haveing a one way valve and a releasable connector
Inventor: PETERS JEAN-PIERRE
IPC: A61M5/00
Filed: 2006-05-23
Abstract: A fluid dispensing system comprising a fluid dispensing unit, a disposable set, and a dosing device is disclosed. The disposable set (5) is for establishing a fluid connection between the fluid dispensing unit and the dosing device which is adapted to dispense the fluid into a patients' vein. The disposable set comprises a length of a tubing (15) for establishing a fluid connection from the dispensing unit towards and into the dosing device, wherein the tubing (15) comprises a first (1) and a second (10) tubing part. The first tubing part (1) is provided to establish a connection to the second tubing part (10) and to the fluid dispensing unit. The second tubing part (10) is provided to establish a connection towards the dosing device and the patient and to the first tubing part (1). The first tubing part (1) comprises a one-way valve (3) which permits a fluid flow from the dispensing unit towards the dosing device and the patient and to prevent a backward fluid flow from the dosing device towards the dispensing unit. The first and second tubing parts are in fluid connection with each other in a liquid tight manner by means of a releasable connection device (12). The connection device (12) permits a back flow from the patient in the direction of the connection device (12) when the connection device (12) is apart and to prevent a back flow from the patient in the direction of the releasable connection device (12) when connected.
Patent NZ-565748-A (NZ)
Title: PI3K inhibitors for the treatment of endometriosis
Inventor: NATARAJA SELVARAJ
IPC: A61K31/00
Filed: 2006-08-28
Abstract: Disclosed is the use of a compound of formula (I), or a salt or isomer thereof, where the substituents are as defined in the specification, as a PI3K inhibitor to treat endometriosis.
Patent NZ-573355-A (NZ)
Title: A lighting device
Inventor: GENEFAAS EDWIN PETER
Filed: 2008-12-01
Abstract: Disclosed is an electronic lighting device for use in vehicle lighting wherein the electronic lighting device is mounted within a chassis pole. Also disclosed is a chassis pole for mounting on a vehicle, wherein the chassis pole includes the lighting device, and a method of providing lighting to a vehicle, wherein the method includes mounting at least one chassis pole to the vehicle chassis and connecting the lighting device to the electronic circuitry of the vehicle via the chassis pole.
Patent NZ-577039-A (NZ)
Title: Peptide-cytotoxic conjugates comprising campthoecin and a somatostatin
Inventor: DONG ZHENG XIN
IPC: A61K38/00
Filed: 2007-10-17
Abstract: Disclosed is a compound according to Formula (IA): A-B-C-E (IA) wherein: A is camptothecin or a derivative thereof; B is rvAhp, rvAla, rvAnc, rvApn, rvArg, rvAsp, ryCha, rvDap(Z), rvGlu or rvPhe; C is D'- D2-D3-D4 wherein D1 is glutaryl, succinyl, or deleted, D2 is (Doc)m wherein m is, independently for each occurrence thereof, 4, 5 or 6 or [Peg]x, wherein x is, independently for each occurrence thereof, 0-100; D3 is (Aepa)n wherein n is, independently for each occurrence thereof, 0 or 1; and D4 is D-Phe or Lys-D-Tyr-D-Tyr; E is a somatostatin analog of the formula c(Cys-A2-A3-D-Trp-Lys-A6-Cys)-A8-R wherein A2 is Phe or deleted; A3 is Phe, 3-(I)Tyr or Tyr, A6 is Abu, Thr or deleted; A8 is Thr or deleted; and R is NH2 or OH; or a pharmaceutically acceptable salt thereof. Also disclosed is a use of the compound, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, in the manufacture of a medicament for treating a disease or condition in a subject in need thereof, wherein said disease or condition is characterized by undesired proliferation of cells that express one or more somatostatin receptors.
Patent NZ-577509-A (NZ)
Title: Crystalline forms of solvated ilaprazole
Inventor: BRACKETT JOHN M
IPC: C07D401/14
Filed: 2007-12-28
Abstract: Disclosed is a crystalline racemic ilaprazole hydrate, which has a powder x-ray diffraction pattern having peaks at 6.5 degrees 2è ± 0.2 degrees 2è and 18.6 degrees 2è ± 0.2 degrees 2è. Also disclosed is the use of the crystalline ilaprazole hydrate for preparing a medicament for treating a gastrointestinal inflammatory disorder in a mammal.
Patent NZ-577731-A (NZ)
Title: Compositions and methods for treatment of multiple sclerosis
Inventor: GELDER FRANK B
IPC: A61K9/16
Filed: 2009-06-16
Abstract: Provided is the use of a composition comprising muramyl dipeptide cross-linked into a micropalticle for the manufacture of a medicament for treating multiple sclerosis. The microparticle is produced from Propionibacter acnes. The composition can be combined with other active agents for therapy.
Patent NZ-578163-A (NZ)
Title: Autonomous systems and methods for still and moving picture production
Inventor: DEANGELIS DOUGLAS J
IPC: H04N5/232
Filed: 2007-12-04
Abstract: Autonomous picture production system comprises a location unit attached to each tracked object (106); an object tracking device (102) for receiving location information from each location unit; at least two motorized cameras (110); and a camera control device (104) for determining which of the motorized cameras has the best field of view of at least one of the tracked objects and for controlling, based upon the location information, the camera with the best field of view to capture image data of the at least one of the tracked objects. The camera control device determines the best field of view based upon factors including presence of another of the tracked objects blocking a view of the at least one of the tracked objects. Also disclosed is an autonomous picture production process comprising automatically determining location of each of a plurality of objects in or adjacent to an operational field; automatically determining whether each of a plurality of motorized cameras has a view of one of the objects obstructed by another of the objects and automatically controlling each of the motorized cameras in response to the location and obstructed views to capture image data of the one object.
Patent NZ-587297-A (NZ)
Title: Use of anti-CGRP (calcitonin gene-related peptide) antagonists to treat inflammatory pain
Inventor: CORRADINI LAURA
IPC: A61K39/395
Filed: 2009-03-03
Abstract: Provided is the use of an anti-CGRP antagonist antibody in the manufacture of a medicament for the prevention and/or treatment of arthritic pain and/or symptoms of arthritic pain, wherein the medicament is prepared to be peripherally administered. The medicament can be administered subcutaneously or intravenously and in combination with other medicaments.
Patent NZ-592151-A (NZ)
Title: Anti-igf antibodies
Inventor: ADAM PAUL
IPC: A61K33/243
Filed: 2009-12-11
Abstract: Disclosed is an isolated human antibody molecule, which a) binds to human IGF-l and IGF-2 such that i) binding of IGF-l and IGF-2 to the IGF-l receptor is prevented and ii) IGF-l receptor-mediated signaling is inhibited, b) binds to mouse and rat IGF-l and IGF-2, does not bind to human insulin; wherein said antibody molecule is c) an antibody molecule that has heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:2l (CDR1), SEQ ID NO:22 (CDR2) and SEQ ID NO:23 (CDR3) and that has light chain CDRs comprising the amino acid sequences of SEQ ID NO:24 (CDR1), SEQ ID NO:25 (CDR2) and SEQ ID NO:26 (CDR3).
Patent NZ-592187-A (NZ)
Title: Basin with removable grate in drain opening
Inventor: CUMMINGS STEPHEN JOHN
IPC: E03C1/26
Filed: 2011-04-11
Abstract: A basin (10) including a bowl depression (12), a drain opening (26) and a grate (28). The bowl depression (12) has, in use, a substantially upstanding wall surface (14). The drain opening (26) is in the wall surface (14) and is adapted for connection to a trap (30). The grate (28) is adapted for releasable engagement with the wall surface (14), within the drain opening (26). In use, the lowermost region of the drain opening (26) is at approximately the same height as, or lower than, the lowermost region of the bowl depression (12). The drain opening (26) is adapted to allow all contents in the bowl depression (12) to drain through the drain opening (26) under the influence of gravity.
Patent NZ-592949-A (NZ)
Title: An injector nozzle and method of manufacture
Inventor: WILSON NEIL
IPC: B29C45/20
Filed: 2008-11-12
Abstract: 592949 Disclosed is an injector tip (3.006) for a mould. The injector tip includes a cooling jacket (3.016) comprising a coolant cavity (3.018) in communication with an undercut cavity (3.030) which surrounds a tapered tip (3.008) of the injector tip. The cooling jacket extends along a majority of the length of an injector duct (3.001). Injection fluid is able to be fed through the hollow core (3.002) of the injector duct. The tip is formed by a direct material deposition process. A method of manufacturing an injector tip is also disclosed whereby the tip is built up from the deposition of consecutive concentric, annular, layers.
Patent NZ-597154-A (NZ)
Title: Immunogenic compositions of staphylococcus aureus antigens
Inventor: ANDERSON ANNALIESA
IPC: A61K38/00
Filed: 2010-06-22
Abstract: 597154 Disclosed is an immunogenic composition comprising: (a) an isolated S. aureus capsular polysaccharide type 5 conjugated to a carrier protein, (b) an isolated S. aureus capsular polysaccharide type 8 conjugated to a carrier protein, and (c) at least one component selected from the group consisting of an isolated S. aureus clumping factor A (ClfA) polypeptide, an isolated S. aureus clumping factor B (ClfB) polypeptide, and an isolated S. aureus manganese transporter protein C (MntC), wherein the capsular polysaccharide type 5 is a high molecular weight capsular polysaccharide of between 70 and 800 kDa, and wherein the capsular polysaccharide type 8 is a high molecular weight capsular polysaccharide of between 70 and 700 kDa. Further disclosed is an immunogenic composition consisting essentially of: (a) an isolated S. aureus capsular polysaccharide type 5 conjugated to a carrier protein, (b) an isolated S. aureus capsular polysaccharide type 8 conjugated to a carrier protein, (c) isolated S. aureus clumping factor A (ClfA) polypeptide, and (d) an isolated S. aureus manganese transporter protein C (MntC), wherein the capsular polysaccharide type 5 is a high molecular weight capsular polysaccharide of between 70 and 800 kDa, wherein the capsular polysaccharide type 8 is a high molecular weight capsular polysaccharide of between 70 and 700 kDa, and wherein the carrier protein is CRM197.
Patent NZ-598853-A (NZ)
Title: Sunscreen compositions
Inventor: PATEL BHALCHANDRA SOMABHAI
IPC: A61K8/27
Filed: 2010-10-12
Abstract: NZ 598853 The disclosure relates to a lip treatment formulation comprising a taste-masked sunscreen composition wherein the taste-masked sunscreen composition comprises at least one organic sunscreen and a spider ester wherein the organic sunscreen and the spider ester are in intimate association; the intimate association being achieved by mixing together the at least one organic sunscreen and the spider ester, and optionally a photostabilizer, to form a pre-mix prior to combining the pre-mix with any other ingredients of the composition; wherein the at least one organic sunscreen is avobenzone; wherein the ratio of the total amount of sunscreen to spider ester is from about 0.6 to about 2 by weight; wherein the spider ester has the common linking group of sorbitol; and at least one ingredient selected from ubiquinone, spilanthes acmella flower extract, hyaluronic acid, a hyaluronic acid salt, and mixtures thereof.
Patent NZ-604306-A (NZ)
Title: Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
Inventor: BABU GOVINDARAJULU
IPC: C07D471/04
Filed: 2011-05-13
Abstract: The present disclosure provides, inter alia, compounds of formula IA and III as protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them. Compounds of the disclosure include:3-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzaldehyde, N-(2-Hydroxyethyl)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl) benzamide, Lithium 4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoate and tert-Butyl 4-(4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamido)piperidine-1-carboxylate
Patent NZ-608133-A (NZ)
Title: Method and device for treating blood cholesterol disorders
Inventor: GRIFOLS ROURA VICTOR
IPC: A61K35/16
Filed: 2013-03-12
Abstract: discloses is the use of whole blood cells without plasma, the plasma being separated from the whole blood cells by plasmapheresis, in the manufacture of a medicament for use in a method of treating cholesterol disorders, wherein the method comprises: administering a first treatment regime comprising two or more rounds of plasmapheresis to a patient having abnormal total cholesterol, abnormal LDL levels and/or abnormal HDL levels when measured before treatment, wherein the first treatment regime decreases LDL levels in patients having abnormal LDL levels and/or increases HDL levels in patients having abnormal HDL levels and, wherein each subsequent round of the first treatment regime maintains the new, lower total cholesterol level, lower LDL level, and/or higher HDL level.
Patent NZ-610990-A (NZ)
Title: Stimulation apparatus
Inventor: ZAMAR ANTONIOS CAMILLE
IPC: A61F5/41
Filed: 2009-09-03
Abstract: Disclosed is an apparatus for applying targeted stimulation at or adjacent the base of the area of the glans of the penis to provide an overall desenistising or tolerising effect towards other stimulation effects. The apparatus comprises a contact portion having a first contact surface conforming substantially to the longitudinal profile of the penis, the contact portion further having a second, domed contact surface, raised, in use, inwardly of the first contact surface towards the penis, to project in use into positive engagement with the area at or adjacent the base of the glans of the penis. The contact portion further includes side wings, which extend substantially circumferentially from either side of the raised second contact surface and profiled for contact, in use, on and around the underside of the corona of the penis, wherein the second contact surface is malleable. The first and/or second contact surfaces and side wings have a plurality of excitation protrusions.
Patent NZ-613857-A (NZ)
Title: Method for producing agrochemical granules
Inventor: TANAKA NOBUYUKI
IPC: A01N25/12
Filed: 2012-02-16
Abstract: The disclosure relates to a method for producing agrochemical granules that contain an agrochemical active ingredient with a solubility in water of 60 ppm or greater, one or more types of hydrophobic substances with a melting point of 50 to 100 degrees Celsius, and an oil-absorbing substance that can be turned to powder. This method comprises (i) obtaining a mixture by mixing the agrochemical active ingredient, the one or more types of hydrophobic substances, and the oil-absorbing substance; (ii) inserting the mixture into a kneading device, heating and kneading at a temperature equal to or greater than the melting point that is the highest of the hydrophobic substances and equal to or lower than 130 degrees Celsius, and then discharging from the kneading device at a temperature that is equal to or lower than the melting point that is the highest of the hydrophobic substances and equal to or higher than 60 degrees Celsius; and a step (iii) granulating the kneaded product using an extrusion molding method. Steps (ii) and (iii) are performed consecutively. The agrochemical active ingredient may be nitenpyram, imidacloprid, acetamiprid, thiamethoxam, clothianidin, thiacloprid, and dinotefuran.
Patent NZ-616735-A (NZ)
Title: Film containing alginate membrane layer and method for preparing same
Inventor: LIN YU-YUEH
IPC: C08L101/16
Filed: 2012-03-20
Abstract: Disclosed is a film containing an alginate membrane layer comprising a film carrier that absorbs liquid and at least one alginate membrane, the alginate membrane being formed by cross-linking between an alginate such as sodium or potassium alginate and a salt water solution comprising a divalent metal ion such as calcium ions. Also disclosed is a manufacturing method of a film containing an alginate membrane, the film comprises a liquid-absorbent film carrier and alginate membrane, the alginate membrane is a hydrogel membrane having a network structure formed by cross linking, the hydrogel membrane with a network structure is formed on and infiltrated into the surface of the film carrier so as to make the alginate membrane unseparated from the film carrier, the manufacturing method of the alginate membrane comprises the steps of: providing an alginate solution containing a percentage of sodium alginate or potassium alginate by weight and a salt water solution containing a percentage of divalent metal ions by weight; providing a length of the liquid-absorbent film carrier; performing a first coating by soaking to coat a layer of the alginate solution on a surface of the film carrier; then performing a second coating by spray coating to coat a layer of the salt water solution over the layer of the alginate solution; and forming an alginate membrane that is a hydrogel membrane having a network structure, formed on and infiltrated into the surface of the film carrier by crosslinking the alginate in the alginate solution with the divalent metal ions in the salt water; wherein the percentage of sodium alginate or potassium alginate in the alginate solution by weight ranges from 1 % to 5% by weight; and wherein the percentage of the divalent metal ions by weight ranges from 1 % to 10% by weight.
Patent NZ-619188-A (NZ)
Title: Stationary wind trainer
Inventor: PHILIPP CLAUS ARTHUR SCHACHT
IPC: A63B69/16
Filed: 2013-12-18
Abstract: 619188 A stationary trainer for use with a bicycle with the rear wheel removed. The stationary trainer has a fan assembly with a fan (2) attached to a fan hub configured to rotate about a fan hub axle (4). The trainer has a drive assembly with a drive hub having at least one gear cog configured to connect with a chain of the bicycle for providing power to the stationary trainer and a chain ring (7), the drive hub configured to rotate about a drive hub axle (8). The drive hub axle (8) is configured to engage with the rear dropouts of the bicycle. The trainer has a chain drive including a chain connecting the chain ring (7) on the drive hub to a cog on the fan hub. There is a first side panel (9) located on a first side of the fan (2) and a second side panel (10) located on a second side of the fan (2) opposite the first side of the fan (2). Bracing elements connect the first side panel (9) to the second side panel (10). The fan assembly and the drive assembly are supported by the first side panel and the second side panel. A distance between an edge of the fan blade and either the first side panel (9) or the second side panel (10) is in the range from 4 mm to 70 mm to result in a reduction in noise from the fan blades compared to a smaller distance.
Patent NZ-619918-A (NZ)
Title: Methods and compositions for diagnosis and prognosis of renal injury and renal failure
Inventor: GRAY JEFF
IPC: G01N33/543
Filed: 2009-10-21
Abstract: Disclosed is a method for evaluating renal status in a subject, comprising: performing one or more assays each assay comprising detecting one or more kidney injury markers present in a body fluid sample obtained previously from the subject, wherein at least one detected kidney injury marker is C-C motif chemokine 5; determining on the body fluid sample one or more assay result(s); and correlating the assay result(s) to the renal status of the subject, said correlating comprising comparing a measured concentration of C-C motif chemokine 5 to a threshold concentration of C-C motif chemokine 5 and assigning a likelihood of an event occurring or assigning a likelihood of an event not occurring when the measured concentration varies from the threshold. Further disclosed is the use of an antibody in a method performed ex vivo in determining an injury to renal function and/or reduced renal function and/or acute renal failure (ARF) and/or a need for renal replacement therapy and/or a need for renal transplantation and/or an improvement in renal function and/or a worsening of renal function in a subject, wherein the antibody binds specifically to C-C motif chemokine 5, and wherein said method is performed on a body fluid sample obtained previously from the subject.
Patent NZ-626658-A (NZ)
Title: Vehicle seat
Inventor: LAMBERT TREVOR EDOUARD
IPC: B60N2/90
Filed: 2012-12-14
Abstract: A vehicle seat such as an aircraft seat (1) comprises a seat pan (2) and a backrest (3). The backrest (3) includes a movable element (16) which is detachable from the backrest and attachable to the seat pan (2) to extend the seat pan surface. The movable element (16) may for example comprise the cushion and supporting structure of the headrest part of the backrest or may comprise just the cushion. Thus, in a row of such seats, an extended bed-like surface may be provided without adding substantially to the weight or bulk of the seat
Patent NZ-627079-A (NZ)
Title: Power supply connection structure device
Inventor: LIN SHIFENG
IPC: H01R43/00
Filed: 2012-01-11
Abstract: Disclosed is a power supply connection structure device for electrically connecting an electrical appliance to a power source. The connections structure device is comprised of: a first electric connection unit; a second electric connection unit; and a control unit which shifts between an idle state and an activation state, wherein in the idle state, the first and second electric connection units are not electrically connected to the power source, and that in the activation state, the control unit electrically connects the first and second electric connection units to the power source, so as to electrically connect an electric circuit between the power supply connection structure device, the power source and the electrical appliance, thereby providing a power supply to the electrical appliance. The power supply connection structure device further comprises a ground wire connection unit which has a ground wire plughole. The control unit is coupled with the ground wire connection unit in such a manner that the control unit is activated by a ground pin which is inserted into the ground wire plughole. The control unit comprises two micro-switches, a push member, two actuation members and a reposition arrangement. Each of the actuation members comprises an actuation arm and a drive arm which is extended from the actuation arm. Each actuation arm is driven by the push member and the reposition arrangement to reciprocate. Each of the micro-switches comprises a resilient element and an electric connection element which is an electric conductive element. When the ground pin is inserted into the ground wire plughole, the push member is driven to move by the ground pin, the actuation arm is pressed by the push member to drive the drive arm to bias against the resilient element, thus the resilient element forces the electric connection element to move, so as to allow the power supply connection structure device to be electrically connected to the power source.